Pfizer Case Solution

7/28/2019 Pfizer Case Solution

1/3

COMPANY OVERVIEW

Since Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849. Pfizer has remained dedicated t

discovering and developing new, and better, ways to prevent and treat disease and improve health and well-bein

for people around the world. From the miracle of penicillin to important medications Pfizer focuses on meetin

the world's diverse health needs. Pfizer is leader in human health, primary care, specialty care, vaccines and biologics.

Pfizer Slogan

A slogan is a short, memorable catch phrase, tagline or motto used to identify a product or companin advertisements. The advertising slogan, or business slogan most associated with Pfizer, is:

"Pfizer Quality."

Pfizer Mission Statement:

"We will become the world's most valued company to patients, customers, colleagues, investors, businesspartners, and the communities where we work and live."

Q.1. Define the Local Situation of Pfizer Pakistan?

Pfizer first set its foot in Pakistan in the 50s and worked with a local distributor through the early 60s. On 8th o

September 1961 Pfizer, established itself as a manufacturing facility in Pakistan by acquiring anothe

incorporated pharmaceutical company. After a few more mergers and acquisitions, today the group oCompanies that operate under the name of Pfizer leads in manufacture and marketing of research base

pharmaceutical products in the country and ranks as a group, at number 3 in the local market.

Q.2. What should be the global strategy of Pfizer in Future?

Pfizer should develop an R&D strategy along with competitive strategy to meet current challenges and positio

itself for high performance in the years ahead. In the end 2013 most of the patents will expire and due to

decreased focus on R&D Pfizer will suffer a lot. Looking at the financial reports of Pfizer their revenue for 201

was 67.425 billion dollars with total stockholders equity over $82bn.

1 This alone puts PF far in the lead of their nearest competitor, Johnson & Johnson, with 15.2% market share.


2/3

2. With a strong revenue stream, they have the ability to further retain earnings into research and developmen

ultimately undermining threatening companies like Merck and GlaxoSmithKline

3. Pfizer should go for diversification in various other areas like organic food, medical instruments etc.

4. the most important step would be to focus on emerging markets like Asia as whole and china in particula

This will give a new birth to the firm.

In General they should go for

New Products & technologies Intellectual Property Protection

Q.3. How should Pfizer do in order to cope up the problem potential and existing problems?

Pharmaceutical companies must react and adapt to the changing market years in the future as opposed to th

current situation. Pfizer must forecast potential dangers facing their market after drugs pass clinical trials. Th

has recently become a problem for Pfizer Inc. In the last few years they have watched their most popular drugs

Blockbusters, lose their patents to less expensive generic alternatives. They reacted to this by downsizing th

R&D department, causing a lack of efficiency and future success. Even though Pfizer has secured the image o

an upward motion with their stockholders, their future earnings as the industry leader is in serious danger.

The good news is; there is a solution. Pfizer can reinstate the former power of the R&D department along with

few efficiency driving factors related to a drugs potential for success. First, Pfizer can reinstate the thousands o

jobs downsized in the last couple years. Second, Pfizer can prioritize certain manufacturing labs to recreate th

fundamental categories of blockbuster pharmaceuticals.

Q.4. What should Pfizer do in the scenarios of multiple mergers and acquisitions?

Pfizer has the huge assets portfolio, the can acquire and merge with many shining pharmacy firms. This is the

requirement of this critical situation where they have no molecule in R&D and the patents will expire soon.

The acquisition of Wyeth is the good step because

Wyeth will bring to Pfizer a number ofmarketed products and pipeline

candidates but is unlikely to address the

Long neglected by drug companies as low-margins therapies, the vaccines market was

transformed by the launch of Wyeths


3/3

fundamental loss of loss of R&D

productivity.

Pfizer has identified six high-potentialdisease areas that would provide the

companys future growth: oncology,

pain, inflammation, diabetes,

Alzheimers disease and schizophrenia.

The acquisition of Wyeth strengthensPfizers position in a number of these key

disease areas, notably Alzheimers

disease and inflammation.

The long term prospects of the oncologyportfolio are also strengthened.

pneumococcal vaccine Prevnar in 2000.

Wyeth has focused heavily on Prevnar andPrevnar-13, to the detriment of its development

pipeline, resulting in only its Phase II meningitis

B vaccine (MnBrLP2086) showing significant

market potential.

Both Pfizer and Wyeth have a strong presence inhospital antibiotics with revenues of $2.5billion

in the seven major markets in 2007 from Zyvox

(Pfizers linezolid), Tygacil (Wyeth tigecycline)

and Zosyn.

Pfizer will now become one of the leadingvaccine manufacturers through accessing

Wyeths vaccines portfolio

Q.5. There would be a shortage of food Worldwide, what sort of strategy Pfizer should adopt?

Biopharmaceutical research companies are helping people lead longer, more productive and healthy lives. Pfizer shouldgo for diversification strategy and must introduce food brands in emerging food market. Genetically modified seeds can

be produced and greater yield will possible if Pfizer will invest in R&D on this side. Ultimately this will generate huge

returns for Pfizer along with a best option to remain in market.

Documents

Pfizer Case Solution